ABSTRACT
withdrawal of activity from the respiratory control center. 1, 2 The disorder often presents as CheyneStokes respiration, a breathing pattern characterized by hyperpnea (cycles of deep, accelerating, crescendo-decrescendo breathing) followed by INTRODUCTION Central sleep apnea (CSA) is a breathing disorder characterized by cessation of airflow in respiratory airways predominantly during sleep, accompanied by cessation of respiratory muscle contraction. This results in temporary pressure and adaptive servoventilation, have been used to treat CSA in patients with systolic HF. These therapies have shown improvements in sleep metrics; however, adaptive servoventilation has shown unfavorable effects in patients with HF with reduced ejection fraction (≤45%). [11] [12] [13] [14] Recently, transvenous PNS was approved by the US Food and Drug Administration for the treatment of moderate to severe CSA in adult patients. 15 Phrenic nerve stimulation contracts the diaphragm and modulates respiration. The anatomical bases for the concept were described previously. 16 Our center is unique in that it is one of a few institutions that participated both in the pilot and pivotal trials.
METHODS The analysis included patients at our center who were enrolled in the pilot and pivotal clinical trials. The remedē System pilot trial (ClinicalTrials.gov, NCT01 124 370) was a prospective, nonrandomized safety and efficacy study, in which patients served as their own controls. We attempted to insert implants in 12 patients (from a total of 57 implant attempts worldwide). The Respicardia, Inc. Pivotal Trial of the remedē System (ClinicalTrials. gov, NCT01816776) was a prospective randomized controlled trial assessing the safety and effectiveness of PNS. We inserted implants in 21 patients (from a total of 151 implant attempts worldwide). The inclusion and exclusion criteria for both trials as well as definitions of the sleep metrics were described previously.
17,18 Studies were performed in compliance with the Declaration of Helsinki, Good Clinical Practice, and ISO-14155:2011. The local ethics committee approved the study protocols for both studies. Serious adverse events (SAEs) related to the implant procedure, device, and delivered therapy hypopnea (slower, shallower breathing) or apnea (no breathing at all with no respiratory effort from the diaphragm and intercostal muscles) (FIGURE 1).
Heart failure (HF) is associated with CSA in up to 40% of patients, but it can be found in other comorbidities including atrial fibrillation, neurologic disorders, chronic renal diseases, and long -term opioid use.
3,4 Increased rehospitalizations and deterioration in cardiac function have been correlated with CSA. 5, 6 Pathological mechanisms include hypoxia, hypercapnia, oxidative stress, systemic inflammation, endothelial dysfunction, sympathetic nervous system activation, and cardiac arrhythmias accompanied by increased therapies from an implanted cardioverter-defibrillator (ICD). [7] [8] [9] Arrhythmias in patients with HF and CSA occur independently of the time of day, which makes the need for treatment even more relevant. We present the results of a comprehensive partnership between cardiology, sleep medicine, and electrophysiology. Between June 2010 and May 2015, cardiology patients were screened for sleep -disordered breathing, and 588 of them were sent for overnight in -home sleep testing. Ninety -six patients were referred for polysomnographic studies based on a preliminary finding of central sleep apnea (CSA), and 33 were enrolled and underwent attempted implantation of a phrenic nerve stimulation (PNS) system. Thirty--one patients successfully received an implant. We showed that transvenous PNS improves sleep metrics, sleep quality, and quality of life in Polish patients with moderate to severe CSA both with and without heart failure. Of importance, device -related events were minimal after the 12-month follow -up, indicating long -term safety. Additionally, the therapy eliminates compliance issues experienced with traditional sleep apnea treatments. This manuscript summarizes the unique experience with the largest group of patients with the remedē® System in a single clinical center. of the Department of Cardiology of the 4th Military Hospital by one operator. Implantation of the remedē® System (Respicardia, Inc., Minnetonka, Minnesota, United States) is similar to cardiac implantable electronic device (CIED) procedures. Briefly, a transvenous stimulation lead is introduced to the vascular system and placed in either the left pericardiophrenic vein or the right brachiocephalic vein following venous access by way of the cephalic, subclavian, or axillary vein. A sensing lead is introduced into the azygos vein. The leads are connected to the remedē® System implantable pulse generator and then secured in a subcutaneous pocket in the pectoral area (FIGURE 2).
Therapy initiation and follow -up Therapy was initiated approximately 30 days after implantation to allow for healing. The exception to this was the control group in the pivotal trial, who had therapy initiated after the assessment of 6-month effectiveness.
In the case of concomitant CIED interactions, testing between the remedē® System and CIED was performed. If an interaction was deemed to pose a clinical risk, the stimulation settings of the remedē® System were changed and the process was repeated in order to demonstrate no further interactions.
After therapy initiation, titration office visits were scheduled. Therapy effectiveness was assessed by patient interview, examination of remedē® System diagnostics, and sleep study data. If the programmed remedē® System settings were determined to be suboptimal, the energy output was usually increased and another titration office visit was scheduled 2 to 4 weeks later. The patient's sleep quality was also assessed by patient symptoms or polygraphy. This titration process facilitated patient acclimation to remedē® System therapy. Follow -up visits were scheduled at every 3 months; in -lab polysomnography studies (scored by the core laboratory) and assessment of QoL using a 7-point patient global assessment scale were done every 6 months.
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Stimulation of the phrenic nerve during sleep in a patient with CSA and the termination of apnea episodes are demonstrated in FIGURE 3. Statistical analysis Differences in baseline characteristics between studies were assessed using the Fisher exact test for categorical data and the analysis of variance for continuous data. Data are presented as mean (SD) or median (IQR) for continuous variables and number (percentage) for categorical variables.
Changes in continuous outcome measures from baseline to 6 and 12 months were tested with the paired t test or nonparametric Wilcoxon signed -rank test if distributional assumptions were not met. Outcome differences between studies were not tested. If the nominal P value was lower than 0.05, the result was considered were collected over 12 months and adjudicated by an independent Clinical Events Committee. All patients gave written informed consent for participation in the study.
Patient identification Potential study candidates were identified by screening the patient database at the 4th Military Hospital in Wrocław, Poland. The following risk factors were used during the prescreening process: obesity, diabetes mellitus, history of tobacco use, arterial hypertension, coronary artery disease, HF (ischemic and nonischemic cardiomyopathy), and atrial fibrillation. Patients were asked about the following symptoms: chronic fatigue, daytime somnolence, somnolence while driving or watching television, and witnessed apneas. A NOX -T3 (Nox Medical Inc., Reykjavík, Iceland) polygraph was used for the in -home sleep test. Sleep tests with at least moderate sleep apnea and evidence of central events were sent to a central core laboratory (Registered Sleepers, Leicester, North Carolina, United States). If the core laboratory identified significant CSA, patients were referred to a local sleep laboratory (EMC -sa.pl) to attend in -lab polysomnography with an electroencephalogram. These polysomnographies were sent to the core laboratory for evaluation. Patients in both trials were eligible if they met the following criteria: apneahypopnea index (AHI) ≥20 events/h, >50% of apneas were of central origin, and ≤20% of the AHI were possible obstructive apneas. For the pivotal trial, an additional criterion was 30 central apneas or more through the night.
Implantation technique and phrenic nerve stimulation All implantations were performed in the Electrophysiological Laboratory (4 of 10 patients in the pilot and 5 of 21 in the pivotal trial). The sensing lead was placed in 22 patients (71%). There were 2 implantation failures in the pilot trial due to anatomical issues: one due to an old thrombosis in the left subclavian vein from a previous procedure and one due to lack of success in achieving acceptable stimulation threshold of the phrenic nerve. Four patients required lead repositioning or replacement, including 3 in the pilot trial and 1 in the pivotal trial. The mean (SD) length of the implantation procedure, from skin to skin was 3.7 (0.8) hours in the pilot trial and 2.7 (0.8) hours (P = 0.003) in the pivotal trial. Pulse generators were exchanged due to normal battery depletion after a mean period of 4 years in 2 patients without any sequelae, which is comparable to the experience of Fox et al.
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Sleep indices Follow -up assessments were conducted in 28 patients at 6 months and in 27 patients at 12 months. At 6 months, there was a mean (SD) reduction in the AHI of 25.5 (15.8) events/h (within -group change from baseline, P <0.001) and at 12 months, a mean (SD) reduction of 29.0 (15.3) events/h (P <0.001), in the pilot trial. Similar AHI reductions of 24.6 (22.9) events/h (P <0.001) at 6 months and of 22.7 (22.7) events/h (P <0.001) at 12 months were observed in the pivotal trial (FIGURE 4).
Improvements in AHI were accompanied by a mean reduction in the CAI and oxygen desaturation index (TABLE 2) . We also observed an improvement in the arousal index at 6 months in the pilot trial and at 6 and 12 months in the pivotal trial.
Improvements in the percentage of rapid eye movement sleep ranged from 4.3 to 9.1 at 6 and 12 months (P ≤0.03 at each visit for each study). The percentage of sleep with O 2 saturation of less than 90% decreased more in the pivotal trial than in the pilot trial (approximately significant. For the effectiveness analysis, pivotal trial participants randomized to the control group, who had the therapy initiated following the 6-month randomized portion of the trial, were pooled with the treatment group participants based on the number of months of active therapy. All follow -up results shown are for months of active therapy. Statistical analyses were performed with SAS (version 9.4, SAS Institute Inc., Cary, North Carolina, United States).
RESULTS Patients' baseline characteristics A total of 200 polygraphy studies followed by 31 polysomnographies were performed between June 2010 and August 2012, resulting in the enrollment of 13 patients in the pilot trial. Between December 2013 and May 2015, 388 polygraphy studies followed by 65 polysomnographies were performed, resulting in the enrollment of 21 patients in the pivotal trial. One patient in the pilot trial voluntarily withdrew consent prior to implantation. Heart failure (defined as a New York Heart Association class I or higher according to the investigator) was present in 12 of the 12 patients (100%) and 14 of the 21 patients (67%) in the pilot and pivotal trials (P = 0.032). There were no significant differences in age, sex, hypertension, atrial fibrillation, diabetes, and body mass index between the trials. The baseline characteristics of patients in each trial are presented in TABLE 1.
Implantation procedure Implantation was successful in all except 2 patients (94%). Of the 31 successfully implanted patients, the stimulation lead was placed in the left pericardiophrenic vein in 22 patients (71%) (6 of 10 patients in the pilot and 16 of 21 patients in the pivotal trial) and in the right brachiocephalic vein in 9 patients (29%) 6% improvement at each visit in the pivotal trial, within -group change P ≤0.02 for each visit, and approximately 3% improvement at each visit in the pilot trial, P = 0.03 and 0.2 at 6 and 12 months, respectively). The OAI after 6 and 12 months of follow -up was stable in both studies. Sleep metrics from the pilot and pivotal trials are presented in Quality of life assessment Following 6 months of therapy, 68% of patients combined across the trials described a marked or moderate improvement, and 11% described a mild improvement in patient global assessment. The results were maintained at 12 months (63% and 19%, respectively; FIGURE 5).
Adverse events No deaths were associated with the implantation procedure. One patient Long -term follow -up data Twelve patients (6 from the pilot and 6 from the pivotal Implant success improved to 100% in the pivotal trial. Additionally, the implantation procedure time decreased by 1 hour (27%) between the pilot and pivotal trials. This is not surprising considering the increasing knowledge of pericardiophrenic vein anatomy and general experience. A shorter duration is clinically important because it reflects a lower risk of infection and reduced fluoroscopy time and anesthesia.
The number of patients experiencing related SAEs remained at an acceptably low level throughout both studies and was comparable with early cardiac resynchronization therapy studies. 24 The rate improved from 25% in the pilot trial to 14% in the pivotal trial, probably due to improved implant tools and more experience.
Limitations The pilot trial was a nonrandomized and open -label study. There were small differences in study protocols. For example, accepted baseline oxygen saturation was 90% or lower in the pilot trial but lower than 92% in the pivotal trial, and the pivotal trial excluded patients with new ICD or any CIED change 30 days prior to baseline testing. Despite recruitment attempts to include women in the trials, only men were enrolled at our center. However, we believe that this had a minor influence on the results because CSA occurs predominantly in men.
25 Owing to stringent enrollment criteria, only 6% of patients undergoing home sleep testing were enrolled in the clinical trial; however, it is likely that many more suffered from some degree of CSA. Finally, the subjective measures of health status and symptoms could be a source of bias.
Conclusions Our center successfully developed and implemented a screening program to identify patients within the cardiology department, with close collaboration between sleep medicine and electrophysiology. Our implant metrics improved over the 2 trials, demonstrating that the technique is feasible and safe as a therapeutic method to treat patients with CSA, and improvements in sleep and QoL were observed. While PNS for the treatment of CSA seems promising, further long -term studies should be performed to assess outcomes such as survival, especially in the HF population.
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The deleterious cardiovascular effects of CSA mediated through intermittent episodes of hypoxia, arousals, activations of the sympathetic nervous system, and other injurious mechanisms lead to increased mortality, particularly in patients with the most severe (≥30 events/h of AHI) sleep -disordered breathing.
23 In our cohort, the reduction in the mean baseline AHI provides evidence that unilateral PNS may influence long -term outcomes (>12 months). Our cohort demonstrated stable OAI at 6 and 12 months, allowing us to conclude that unilateral PNS does not contribute to upper airway collapse. a When the stimulation lead was pulled out of the target vessel and required repositioning or replacement to deliver therapy.
b When the lead remained in the target vessel but the electrode position did not allow effective delivery of therapy.
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